Overview:
Kidney Panel KFT ProfileIntroduction: The Kidney Panel KFT Profile is a diagnostic tool designed for basic kidney function screening using serum and urine samples. Associated with conditions like chronic kidney disease and acute kidney injury, these disorders present with edema, fatigue, and severe complications if untreated, particularly in individuals with suspected kidney issues. Per the 2023 Biochemistry and Clinical Pathology guidelines, the test employs biochemistry and clinical pathology with spectrophotometry and microscopy technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for kidney function monitoring in clinical settings. This diagnostic falls under kidney function monitoring and targets individuals with suspected kidney disease, addressing the challenge of accurate parameter assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its dual-sample approach ensures reliable detection.
Other Names: KFT Pfl.
FDA Status: FDA approved, CLIA certified for biochemistry and clinical pathology, compliant with 2025 standards.
Historical Milestone: Introduced in the 1980s by clinical labs, this test advanced basic kidney function screening.
Purpose: The test screens for 16 parameters including creatinine to guide kidney assessment, assess renal function, and inform treatment and prevention strategies.
Test Parameters: 1. Creatinine, 2. Urea, 3. eGFR, 4. Sodium, 5. Potassium, 6. Chloride, 7. Calcium, 8. Phosphorus, 9. Uric Acid, 10. Total Protein, 11. Albumin, 12. Globulin, 13. Urine Protein, 14. Urine Creatinine, 15. Urine Albumin/Creatinine Ratio, 16. Urine Microalbumin.
Pretest Condition: Fasting 10-12 hours required; patients should report edema, fatigue, or recent kidney symptoms.
Specimen: 3 mL serum in 1 SST, 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours (Serum), 24 hours (Urine) with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days (Serum, Urine) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months (Serum, Urine) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on edema, fatigue, prior kidney reactions, or family history of renal disease, as well as any recent trauma or treatments.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated kidney disease including renal failure, benefits of early detection, and minimal discomfort from sample collection.
Procedural Considerations: The test involves sample processing using spectrophotometry and microscopy and interpret results within 1-2 days using provided controls.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent medication use can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Abnormal results indicate possible kidney disease, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist.
Specialist Consultation: General practitioners or specialists in nephrology should be consulted for case management, treatment planning, and coordination with health programs.
Additional Supporting Tests: Renal ultrasound or biopsy for confirmation.
Test Limitations: The test may produce false negatives in early disease stages or false positives in acute illness, requiring a comprehensive diagnostic approach that includes clinical correlation.
References: Biochemistry and Clinical Pathology Guidelines 2023, Journal of Nephrology 2024, Chemistry 2025.
